Source Paper
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice
Bin Zhang, Jenna Carroll, John Q. Trojanowski, Yuemang Yao, Michiyo Iba et al.
Journal of Neuroscience • 2012
Cognitive Performance Testing
Objective: Evaluation of cognitive performance and behavioral deficits in aged PS19 mice treated with epothilone D to assess whether MT-stabilizing treatment improves cognitive function in a transgenic tau pathology model
Gather these items before starting the experiment. Check off items as you prepare.
Materials1
not specified • not specified • not specified • not specified
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Animal Treatment
Aged PS19 mice with existing tau pathology were treated with epothilone D
Note: Treatment was interventional in nature, administered to mice with pre-existing tau pathology
View evidence from paper
“interventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mice with existing tau pathology”
Cognitive Performance Assessment
Cognitive performance was evaluated in treated and control PS19 mice
Note: Specific cognitive tests and behavioral assessment methods are not detailed in the provided text
View evidence from paper
“EpoD treatment reduced axonal dystrophy and increased axonal MT density in the aged PS19 mice, which led to improved fast axonal transport and cognitive performance”
Behavioral Deficit Evaluation
Behavioral deficits related to tau pathology were assessed in treated mice
Note: Mice had related behavioral deficits at baseline due to tau pathology
View evidence from paper
“aged PS19 mice with existing tau pathology and related behavioral deficits”